Identification of Chitinase-3-Like Protein 1 as a Novel Neutrophil Antigenic Target in Crohn's Disease.
Adolescent
Adult
Antibodies, Antineutrophil Cytoplasmic
/ blood
Autoantibodies
/ immunology
Biomarkers
/ blood
Blotting, Western
Case-Control Studies
Child
Chitinase-3-Like Protein 1
/ immunology
Crohn Disease
/ immunology
Enzyme-Linked Immunosorbent Assay
Female
Germany
Humans
Immunoglobulins
/ immunology
Male
Neutrophils
/ immunology
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Crohn’s disease
Inflammatory bowel disease
autoantibody
chitinase-3 like protein 1
enzyme-linked immunosorbent assay
Journal
Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676
Informations de publication
Date de publication:
25 Jul 2019
25 Jul 2019
Historique:
pubmed:
13
2
2019
medline:
25
1
2020
entrez:
13
2
2019
Statut:
ppublish
Résumé
There is an increasing incidence of inflammatory bowel disease [IBD]. Autoimmune responses are involved in the pathophysiology of IBD, but their underlying pathways and target antigens have not yet been fully elucidated. Autoantigenic targets in IBD were identified after separation of whole cell proteins isolated from neutrophils using two-dimensional electrophoresis and matrix assisted laser desorption ionization - time of flight mass spectrometry-based protein identification of the spots that displayed Western blotting signals with anti-neutrophil cytoplasmic antibody-positive sera. The prevalence of IgG, IgA and secretory IgA [sIgA] to chitinase 3-like protein 1 [CHI3L1] was analysed by enzyme-linked immunosorbent assays using recombinant CHI3L1 in 110 patients with Crohn's disease [CD], 95 with ulcerative colitis [UC], 126 with coeliac disease [CeD] and 86 healthy controls [HCs]. The 18-glycosylhydrolase family member CHI3L1 was identified as a neutrophil autoantigenic target. CD patients displayed significantly higher levels of IgG to CHI3L1 than patients with UC and CeD (p < 0.0001, respectively). IgA and sIgA to CHI3L1 was significantly higher in CD than in UC, CeD and HCs [p < 0.0001, respectively]. IgA and sIgA to CHI3L1 demonstrated the highest prevalence in CD [25.5%, 28/110; and 41.8%%, 46/110] compared to HCs [2.3%, 2/86; and 4.7%%, 4/86; p = 0.0015 and p < 0.0001] and are associated with a more complicated progression of CD. CHI3L1 is a novel neutrophil autoantigenic target in CD. IgA and sIgA to CHI3L1 may serve as novel markers for CD and may facilitate the serological diagnosis of IBD.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
There is an increasing incidence of inflammatory bowel disease [IBD]. Autoimmune responses are involved in the pathophysiology of IBD, but their underlying pathways and target antigens have not yet been fully elucidated.
METHODS
METHODS
Autoantigenic targets in IBD were identified after separation of whole cell proteins isolated from neutrophils using two-dimensional electrophoresis and matrix assisted laser desorption ionization - time of flight mass spectrometry-based protein identification of the spots that displayed Western blotting signals with anti-neutrophil cytoplasmic antibody-positive sera. The prevalence of IgG, IgA and secretory IgA [sIgA] to chitinase 3-like protein 1 [CHI3L1] was analysed by enzyme-linked immunosorbent assays using recombinant CHI3L1 in 110 patients with Crohn's disease [CD], 95 with ulcerative colitis [UC], 126 with coeliac disease [CeD] and 86 healthy controls [HCs].
RESULTS
RESULTS
The 18-glycosylhydrolase family member CHI3L1 was identified as a neutrophil autoantigenic target. CD patients displayed significantly higher levels of IgG to CHI3L1 than patients with UC and CeD (p < 0.0001, respectively). IgA and sIgA to CHI3L1 was significantly higher in CD than in UC, CeD and HCs [p < 0.0001, respectively]. IgA and sIgA to CHI3L1 demonstrated the highest prevalence in CD [25.5%, 28/110; and 41.8%%, 46/110] compared to HCs [2.3%, 2/86; and 4.7%%, 4/86; p = 0.0015 and p < 0.0001] and are associated with a more complicated progression of CD.
CONCLUSION
CONCLUSIONS
CHI3L1 is a novel neutrophil autoantigenic target in CD. IgA and sIgA to CHI3L1 may serve as novel markers for CD and may facilitate the serological diagnosis of IBD.
Identifiants
pubmed: 30753386
pii: 5308524
doi: 10.1093/ecco-jcc/jjz012
pmc: PMC6657965
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
Autoantibodies
0
Biomarkers
0
Chitinase-3-Like Protein 1
0
Immunoglobulins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
894-904Informations de copyright
© European Crohn’s and Colitis Organisation (ECCO) 2019.
Références
Exp Cell Res. 1999 Jul 10;250(1):168-73
pubmed: 10388530
Rheumatology (Oxford). 1999 Jul;38(7):618-26
pubmed: 10461474
Rheumatology (Oxford). 1999 Nov;38 Suppl 2:8-10
pubmed: 10646482
Osteoarthritis Cartilage. 2001 Apr;9(3):203-14
pubmed: 11300743
Biochem Biophys Res Commun. 2001 Jul 27;285(4):926-31
pubmed: 11467840
Clin Exp Rheumatol. 2001 Nov-Dec;19(6):655-60
pubmed: 11791636
Eur J Gastroenterol Hepatol. 2002 Feb;14(2):129-35
pubmed: 11981336
Biochem J. 2002 Jul 1;365(Pt 1):119-26
pubmed: 12071845
Int J Colorectal Dis. 2003 May;18(3):254-9
pubmed: 12673492
J Biol Chem. 2003 Aug 8;278(32):30206-12
pubmed: 12775711
Exp Cell Res. 2003 Jul 1;287(1):79-87
pubmed: 12799184
Scand J Gastroenterol. 2003 Jun;38(6):599-605
pubmed: 12825867
Electrophoresis. 2004 May;25(9):1327-33
pubmed: 15174055
Inflamm Bowel Dis. 2005 Aug;11(8):707-12
pubmed: 16043984
Clin Chem. 2006 Feb;52(2):171-81
pubmed: 16339302
Gastroenterology. 2006 Feb;130(2):398-411
pubmed: 16472595
Inflamm Bowel Dis. 2007 Oct;13(10):1277-83
pubmed: 17476674
Lancet. 2007 May 12;369(9573):1627-40
pubmed: 17499605
Nature. 2007 Jul 26;448(7152):427-34
pubmed: 17653185
J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 2):e357-62
pubmed: 17725598
Scand J Gastroenterol. 2007 Dec;42(12):1440-4
pubmed: 17852860
Lab Invest. 2008 Aug;88(8):883-95
pubmed: 18490894
Immunity. 2008 Jun;28(6):740-50
pubmed: 18549797
Gut. 2009 Dec;58(12):1620-8
pubmed: 19549613
Arch Immunol Ther Exp (Warsz). 2009 Jul-Aug;57(4):291-4
pubmed: 19578817
Am J Gastroenterol. 2010 Jan;105(1):162-9
pubmed: 19755969
Nature. 2009 Nov 12;462(7270):226-30
pubmed: 19907495
Wien Klin Wochenschr. 2010 May;122 Suppl 2:19-25
pubmed: 20517666
Clin Immunol. 2011 Sep;140(3):268-75
pubmed: 21546314
Aliment Pharmacol Ther. 2011 Oct;34(8):941-8
pubmed: 21848856
Mucosal Immunol. 2011 Nov;4(6):603-11
pubmed: 21975936
J Immunol. 2012 Sep 15;189(6):2774-83
pubmed: 22891285
Toxicol Appl Pharmacol. 2013 Jun 15;269(3):307-16
pubmed: 23583300
Gastroenterology. 2013 Sep;145(3):602-12.e9
pubmed: 23684751
Biochem J. 1990 Jul 1;269(1):265-8
pubmed: 2375755
Gut. 2013 Oct;62(10):1505-10
pubmed: 24037875
Autoimmun Rev. 2014 Apr-May;13(4-5):467-71
pubmed: 24424189
Autoimmun Rev. 2014 Apr-May;13(4-5):463-6
pubmed: 24424198
World J Gastroenterol. 2014 Mar 28;20(12):3255-64
pubmed: 24695798
Middle East J Dig Dis. 2013 Apr;5(2):93-7
pubmed: 24829676
J Immunol Res. 2014;2014:185416
pubmed: 24995343
PLoS One. 2014 Sep 16;9(9):e107743
pubmed: 25225805
Biochem Biophys Res Commun. 2015 Jan 2;456(1):202-6
pubmed: 25446124
Immunol Rev. 2015 Nov;268(1):123-38
pubmed: 26497517
J Clin Invest. 1989 Oct;84(4):1045-9
pubmed: 2677047
Aliment Pharmacol Ther. 2016 May;43(10):1069-79
pubmed: 26953251
Dig Dis. 2016;34(1-2):90-7
pubmed: 26982193
J Clin Med. 2016 Dec 17;5(12):null
pubmed: 27999328
J Dig Dis. 2017 Sep;18(9):495-503
pubmed: 28857501
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
Pathophysiology. 2018 Dec;25(4):253-262
pubmed: 30266339
J Biol Chem. 1995 Jun 2;270(22):13076-83
pubmed: 7768902
J Clin Pathol. 1994 Jan;47(1):4-8
pubmed: 8132808
Br J Rheumatol. 1993 Nov;32(11):949-55
pubmed: 8220933
J Biol Chem. 1993 Dec 5;268(34):25803-10
pubmed: 8245017
Gut. 1994 Feb;35(2):224-30
pubmed: 8307474
Gut. 1997 Apr;40(4):443-8
pubmed: 9176068
Eur J Biochem. 1998 Jan 15;251(1-2):504-9
pubmed: 9492324
Proc Assoc Am Physicians. 1998 Jul-Aug;110(4):351-60
pubmed: 9686683
Gut. 1998 Jun;42(6):788-91
pubmed: 9691915